Table 5 Relationship between baseline characteristics and VA at the 12-month follow-up
From: Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
Baseline Characteristic | P value of the univariate analysis of baseline characteristics and VA at the 12-month follow-up | P value of the multivariate analysis of baseline characteristics and VA at the 12-month follow-up |
|---|---|---|
Age | 0.24 | |
Gender | 0.16 | |
Baseline VA | < 0.01 | < 0.01 |
Baseline CRT | < 0.01 | |
PED | 0.05 | |
Retinal/subretinal hemorrhage | < 0.01 | |
Subretinal fluids | < 0.01 | < 0.01 |
CNV | 0.91 | |
Lesion location | 0.90 | |
Greatest lesion diameter | 0.01 | < 0.01 |